Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended December 31, 2017, and the six-month period ending on that date. The registrant is an Australian biotechnology entity subject to ASX Listing Rule 4.7B, reporting cash flow activities rather than full revenue or profit metrics.
Key Financial Metrics
Cash Flow (Current Quarter ended Dec 31, 2017):
- Net Cash from Operating Activities: $672,000 AUD (Positive, driven by government grants).
- Net Cash from Investing Activities: ($3,000) AUD.
- Net Cash from Financing Activities: $44,000 AUD.
- Net Increase in Cash: $19,348,000 AUD (Significant increase due to exchange rate movements).
- Cash and Cash Equivalents at Period End: $20,030,000 AUD.
Operating Expenditures (Current Quarter):
- Research and Development: $1,018,000 AUD.
- Staff Costs: $901,000 AUD.
- Administration and Corporate Costs: $421,000 AUD.
- Advertising and Marketing: $16,000 AUD.
Revenue and Profit: The filing text does not provide a clear value for revenue or net profit, as the report focuses exclusively on cash flows. No receipts from customers were recorded in the current quarter.
Debt and Liquidity: The company reported no loan facilities drawn and no borrowings. Liquidity is supported by bank balances of $10,030,000 AUD and call deposits of $10,000,000 AUD.
Material Changes
Government Grants: The company received $3,023,000 AUD in government grants and tax incentives during the quarter, which was the primary driver turning operating cash flow positive despite significant R&D and staff expenditures.
Exchange Rate Impact: A favorable movement in exchange rates contributed $31,000 AUD to the cash balance in the current quarter and $610,000 AUD over the six-month period.
Year-to-Date Comparison: Over the six months ended December 31, 2017, operating cash flow was negative at ($1,285,000) AUD, contrasting with the positive $672,000 AUD in the single quarter, indicating the grants were received primarily in the final quarter.
Outlook and Risks
Estimated Cash Outflows (Next Quarter): Management estimates total cash outflows of $3,925,000 AUD for the upcoming quarter. Key components include:
- Research and Development: $1,418,000 AUD.
- Staff Costs: $934,000 AUD.
- Administration and Corporate Costs: $918,000 AUD.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard requirement to maintain cash reserves for ongoing R&D. The company relies on government grants to offset operating costs, as no customer receipts were recorded.
Investor Verification Checklist
- Verify the sustainability of the $3.023 million government grant received in Q4 2017 and whether similar funding is expected in future quarters.
- Confirm the company's cash runway given the estimated $3.925 million outflow for the next quarter against the $20.03 million cash balance.
- Investigate the source of the significant $19.3 million increase in cash, which appears largely driven by exchange rate fluctuations rather than operational cash generation.
- Review the status of product development to understand when customer receipts might begin to offset R&D expenditures.